CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database

作者: D-P Dai , R-A Xu , L-M Hu , S-H Wang , P-W Geng

DOI: 10.1038/TPJ.2013.2

关键词:

摘要: Genetic polymorphisms of CYP2C9 significantly influence the pharmacokinetics and pharmacodynamics some drugs, which might result in adverse drug effects therapeutic failure. Several studies have been performed on genetic Han Chinese populations. However, these only focused two commonly investigated alleles, *2 *3, relatively small sample sizes. To scale up gene-scanning region determine precise data distribution pattern populations, unrelated healthy volunteers from Zhejiang Province (n=1127) Hebei (n=1000) were recruited as subjects for direct sequencing all exons CYP2C9. As a result, 14 previously reported alleles detected this work, 8 (*14, *16, *19, *23, *27, *29, *33 *34) described first time In addition, 37 novel mutations also detected, 22 variants non-synonymous, 21 new *36-*56, designated by Human CYP Allele Nomenclature Committee. vitro functional analysis revealed that 17 had significant protein’s catalytic activity. Our study provides most accurate populations detects largest number allelic existing to date. These will greatly enrich current knowledge naturally occurring

参考文章(56)
Wan Mohd Nowalid Wan Khairina, Harris Abdullah Ngow, Roslan Harun, Rusli Ismail, Mohd Zaki Salleh, Lay Kek Teh, Wee Leng Lee, CYP2C9 polymorphism: Prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia Singapore Medical Journal. ,vol. 50, pp. 490- 493 ,(2009)
Arintaya Phrommintikul, Srun Kuanprasert, Poonsub Palacajornsuk, Warunee Kunachiwa, Sakchai Dettrairat, Prevalence of CYP2C9 and VKORC1 mutation in patients with valvular heart disease in Northern Thailand Journal of the Medical Association of Thailand Chotmaihet thangphaet. ,vol. 92, pp. 1597- 1601 ,(2009)
Abdul Khaliq Naveed, Dilshad Ahmad Khan, Aisha Siddiqi, Farooq Ahmed Khan, Impact of CYP2C9 genetic polymorphism on warfarin dose requirements in Pakistani population. Pakistan Journal of Pharmaceutical Sciences. ,vol. 23, pp. 417- 422 ,(2010)
Sükrü Aynacioglu, Jürgen Brockmöller, Steffen Bauer, Christoph Sachse, Pinar Güzelbey, Zuhal Öngen, Muradiye Nacak, Ivar Roots, Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin British Journal of Clinical Pharmacology. ,vol. 48, pp. 409- 415 ,(1999) , 10.1046/J.1365-2125.1999.00012.X
H. W. Lee, M.-s. Lim, J. Lee, M.-Y. Jegal, D.-W. Kim, W.-K. Lee, I.-J. Jang, J.-G. Shin, Y.-R. Yoon, Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics Journal of Clinical Pharmacy and Therapeutics. ,vol. 37, pp. 105- 111 ,(2012) , 10.1111/J.1365-2710.2010.01238.X
Jue Quin Yang, Sandrine Morin, C��line Verstuyft, Li An. Fan, Yong Zhang, Chun Di Xu, V��ronique Barbu, Patrice Jaillon, Laurent Becquemont, Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundamental & Clinical Pharmacology. ,vol. 17, pp. 373- 376 ,(2003) , 10.1046/J.1472-8206.2003.00148.X
Hedi Schelleman, Colleen M. Brensinger, Jinbo Chen, Brian S. Finkelman, Mark J. Rieder, Stephen E. Kimmel, New genetic variant that might improve warfarin dose prediction in African Americans British Journal of Clinical Pharmacology. ,vol. 70, pp. 393- 399 ,(2010) , 10.1111/J.1365-2125.2010.03709.X
A ALLABI, Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clinical Pharmacology & Therapeutics. ,vol. 76, pp. 113- 118 ,(2004) , 10.1016/J.CLPT.2004.04.001
Maria Gabriella Scordo, Eleni Aklillu, Umit Yasar, Marja-Liisa Dahl, Edoardo Spina, Magnus Ingelman-Sundberg, Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. British Journal of Clinical Pharmacology. ,vol. 52, pp. 447- 450 ,(2001) , 10.1046/J.0306-5251.2001.01460.X
Aurel C. Allabi, Jean-Luc Gala, Yves Horsmans, CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population Pharmacogenetics and Genomics. ,vol. 15, pp. 779- 786 ,(2005) , 10.1097/01.FPC.0000174787.92861.91